94-15470. Opportunity For Licensing: Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus

[Federal Register Volume 59, Number 122 (Monday, June 27, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-15470]


[[Page Unknown]]

[Federal Register: June 27, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Opportunity For Licensing: Neutralizing Monoclonal Antibodies for 
Respiratory Syncytial Virus

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH), Department of Health 
and Human Services (DHHS), seeks licensee(s) who can effectively pursue 
the preclinical, clinical and commercial development of human 
monoclonal antibodies against respiratory syncytial virus (RSV). NIH 
intends to grant the selected firm(s) world-wide royalty-bearing 
license(s) to practice the inventions embodied in U.S. Patent 
Application SN 07/945,515 entitled ``Human Neutralizing Monoclonal 
Antibodies for Respiratory Syncytial Virus'' and related foreign patent 
applications for all or some of the available fields of use. The patent 
rights in these inventions have been jointly assigned to the United 
States of America and The Scripps Research Institute.

SUPPLEMENTARY INFORMATION: The NIH seeks licensee(s), who in accordance 
with requirements and regulations governing the licensing of 
government-owned inventions (37 CFR part 404), have the most 
meritorious plan for the development of RSV monoclonal antibodies for 
the treatment or prevention of RSV infections to a marketable status to 
meet the needs of the public and with the best terms for the NIH. The 
criteria that NIH will use to evaluate license applications will 
include, but not be limited to those set forth by 37 CFR 
404.7(a)(1)(ii)-(iv).

DATES: In view of the high priority for developing prophylactics for 
the treatment of RSV infection, all proposals must be received on or 
before July 27, 1994.

ADDRESSES: Requests for a copy of the patent applications, license 
application form, or other questions and comments concerning the 
licensing of this technology should be directed to: Mark D. Hankins 
Esq., Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804. Telephone: [phone] ext. 265; 
Facsimile: [phone].
    A signed confidentiality agreement will be required to receive 
copies of the patent applications.

    Dated: June 15, 1994.
Barbara M. McGarey, J.D.
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-15470 Filed 6-24-94; 8:45 am]
BILLING CODE 4140-01-P